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If at once you don’t succeed, should we really try,
try again?
Sergio GiraltIn this edition of Biology of Blood and Marrow
Transplantation, Jimenez-Zepeda et al. [1] explore the
role of a second autologous stem cell transplant
(ASCT) as salvage therapy for patients with multiple
myeloma. Although all the pitfalls and caveats regard-
ing retrospective reviews apply to this analysis (ie, se-
lection bias, uncertain denominator, patient and
treatment heterogeneity, etc.), we can learn from this
17-year single institutional experience.
Salvage high-dose therapy with ASCT improved
responses to induction therapy in most patients.
Complete remission rates increased from 0% to
7.7%; very good partial response rates increased
from 12.5% to 39.7% with partial remission or
greater rates increasing from 86.2% to 97.4%. The
median time to relapse after transplant was 19
months, and treatment-related deaths occurred in2.6% of patients. As reported by others, remission du-
ration after the first autograft predicts response and
remission duration after a second autograft. Patients
relapsing within 24 months of their initial autograft
had a median progression-free survival of 9.8 months,
whereas patients whose remission duration lasted
more than 2 years had a progression-free survival of
17.3 months. Looking at these data, it is important
to note that these patients were selected based on
their response to re-induction therapy. In contrast,
more than 20 years ago, Jagannath et al. [2] reported
on 21 patients who were resistant to standard
melphalan-prednisone and vincristine, adriamycin,
dexamethasone and received high-dose therapy with
bone marrow support. Five toxic deaths occurred in
these patients with refractory relapsed myeloma and
the remission duration was approximately 7 months.
Thus, this strategy is not optimally effective in multi-
ply relapsed and refractory patients.
The report of Jimenez-Pineda et al. [1] confirms
previous reports of the use of high-dose therapy with
ASCT as consolidation therapy for patients relapsing
after primary therapy. Response rates of greater than
75% are routinely reported, but with few patients
achieving a complete remission. Remission durations
of 12 to 18 months are usually reported with a fraction
of patients having long-term disease control. In all re-
ports, chemosensitivity as well as duration of myeloma
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important prognostic factors for subsequent long-
term disease control. Contrasting these results to
non-transplant-based salvage therapy in which re-
sponse rates of 50% are reported, with remission dura-
tions of less than a year, we are left with the question of
why are we not doing more salvage ASCTs [3]. Indeed,
in a recent Center for International Blood andMarrow
Transplant Research analysis over a 13-year period,
only 187 patients reportedly underwent a second
ASCT as salvage therapy for myeloma [4]. Without
a doubt, one of the main barriers to a more in-depth
exploration of a second ASCT is insurance approval
(Medicare only covers one ASCT during a patient’s
lifetime.), but lack of comparative prospective trials
looking at the role of second ASCT as consolidation
therapy for patients relapsing after primary therapy.
Likewise, concerted efforts need to be made to reduce
the treatment burden of patients undergoing ASCT,
because for many patients, the idea of spending an-
other ‘‘4 weeks in the hospital’’ and ‘‘months away
from work’’ is a non-starter, particularly if the thera-
peutic benefit is uncertain. Although not addressed,
the role of allogeneic stem cell transplantation (SCT)
as salvage therapy also remains uncertain and needs
to be prospectively explored.BOTTOM LINE
Salvage autologous SCT is effective consolidation
therapy for patients with myeloma: however, moreprospective trials need to be performed in this setting,
which also includes the appropriate patient population
to study new conditioning regimens and novel mainte-
nance strategies. The role of the stem cell source (allo
versus auto), as well as optimal conditioning regimens
and post-SCT maintenance, need to be defined. Based
on these results and other retrospective analyses, sal-
vage SCT should not be relegated to a ‘‘last-ditch ef-
fort’’ in patients who have failed all prior therapies,
but should be considered an integral component of sal-
vage strategies.ACKNOWLEDGMENT
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